U.S., Sept. 9 -- ClinicalTrials.gov registry received information related to the study (NCT07160400) titled 'A Study of IBI3032 in Chinese Healthy Participants and Participants With Overweight or Obesity' on Aug. 21.
Brief Summary: This is a randomized, double-blind, placebo-controlled phase 1 clinical study evaluating the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of a single ascending dose of IBI3032 in healthy participants and multiple ascending doses of IBI3032 in participants with overweight or obesity. It consists of 2 parts: Part A is a single ascending dose (SAD) study in healthy participants, and Part B is a multiple ascending dose (MAD) study in participants with overweight or obesity during the 4-week...